Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

PURPOSE: Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal antibody against IGF-IR. Here, we explore the therapeutic potential of ganitumab for the treatment of ovarian cancer. EXPERIMENTA...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Beltran, Pedro J., Calzone, Frank J., Mitchell, Petia, Chung, Young-Ah, Cajulis, Elaina, Moody, Gordon, Belmontes, Brian, Li, Chi-Ming, Vonderfecht, Steven, Velculescu, Victor E., Yang, Guorong, Qi, Jingwei, Slamon, Dennis J., Konecny, Gottfried E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4138720/
https://ncbi.nlm.nih.gov/pubmed/24727326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-3448
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak